Summit Therapeutics reports survival benefit for cancer drug in trial

What happened: Summit Therapeutics (SMMT) said its experimental cancer drug ivonescimab helped patients with advanced biliary tract cancer live significantly longer than those receiving an established immunotherapy in a late-stage trial conducted in China. Key numbers: Median overall survival 14.9 Why it matters: The survival advantage over an established therapy strengthens the case for further development and could expand commercial opportunities beyond lung cancer, though the findings come from a study conducted exclusively in China and U.S. approval still requires further evidence. Market: -0.6% today ($171.49), -5.4% YTD, 1.4x vol — as of 22:46 UTC Coverage: 3 outlets in 24h

Summit Therapeutics (SMMT) said its experimental cancer drug ivonescimab helped patients with advanced biliary tract cancer live significantly longer than those receiving an established immunotherapy in a late-stage trial conducted in China.

The survival advantage over an established therapy strengthens the case for further development and could expand commercial opportunities beyond lung cancer, though the findings come from a study conducted exclusively in China and U.S. approval still requires further evidence. Market: -0.6% today ($171.49), -5.4% YTD, 1.4x vol — as of 22:46 UTC